Work

O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.05.013

Authors: M. Ducreux, J. Tabernero, A. Grothey, D. Arnold, P. O'Dwyer, M. Perdicchio, Z. Assaf, M. Das Thakur, N. Irahara, A. Tahiri, H. Schmoll, E. Van Cutsem, A. de Gramont

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, West Cancer Center, Asklepios Klinik Altona, Asklepios, Abramson Cancer Center, University of Pennsylvania, F. Hoffmann-La Roche AG, Genentech, Martin Luther University Halle-Wittenberg, Universitair Ziekenhuis Leuven, KU Leuven, Institut Hospitalier Franco Britannique

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Merck, Roche, Sanofi, F. Hoffmann-La Roche, Genentech

OpenAlex ID: W3191617288

FWCI: 0.091

Cites:

Cited by: 2

Related to: 10